If you have a high tolerance for risk, then it could be worth considering the speculative ASX stock in this article.
That's the view of analysts at Bell Potter, which are tipping its shares to rise very strongly from where they trade today.
Which speculative ASX stock?
The stock that Bell Potter is feeling bullish on is Clarity Pharmaceuticals Ltd (ASX: CU6).
It is a clinical stage radiopharmaceutical company that is focused on the treatment of serious diseases. The company notes that it is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.
Clarity Pharmaceuticals also highlights that unlike other commercially available chelators, its SAR technology prevents copper leakage into the body.
What did the broker say about the company?
Bell Potter notes that the speculative ASX stock has been very volatile recently. It said:
The volatility in the CU6 share price in recent weeks is likely the outcome of a series of highly positive announcements from progress in clinical trials, index inclusion (in the ASX300) and profit taking. Investors who took the March 2024 placement at $2.55 and sold at the peak ($8.97 – 23 September 2024) recorded a 250% return in 6 months.
However, it feels investors should look beyond its volatile share price and focus on the good things that are happening. The broker adds:
The factors driving initial interest remain firmly in place and these include a) clinical data – both for imaging and therapy applications remains highly encouraging, and b) M&A interest in radiopharmaceutical assets remains.
In light of this, this morning, Bell Potter has reaffirmed its speculative buy rating and $10.00 price target on the company's shares. Based on its current share price of $6.70, this implies potential upside of approximately 49% for investors over the next 12 months.
To put that into context, a $5,000 investment in this ASX stock would be worth almost $7,500 in 12 months if Bell Potter is on the money with its recommendation.
In its conclusion, the broker revealed that it remains very positive on Clarity Pharmaceuticals following recent trial updates. It said:
There are no changes to earnings and we remain highly encouraged by the responses reported in the therapy trials. CU6 remains well funded with cash and liquid assets at 30 June of ~$146m representing funding deep into CY26. Valuation unchanged at $10.00.
